drugset / Trial / NCT01058018

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

NCT01058018

Phase 2 Completed 299 enrolled Resverlogix Corp
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate dose range, safety and efficacy of RVX000222 in subjects with stable coronary artery disease.

Timeline

Start
2009-12
Primary completion
2010-06
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Apabetalone Small molecule 50 mg Oral
Subject Apabetalone Small molecule 100 mg Oral
Subject Apabetalone Small molecule 150 mg Oral